Page last updated: 2024-10-27

fluconazole and Ventilator-Associated Pneumonia

fluconazole has been researched along with Ventilator-Associated Pneumonia in 2 studies

Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Manzoni, P1
De Luca, D1
Stronati, M1
Jacqz-Aigrain, E1
Ruffinazzi, G1
Luparia, M1
Tavella, E1
Boano, E1
Castagnola, E1
Mostert, M1
Farina, D1
Nseir, S1
Jozefowicz, E1
Cavestri, B1
Sendid, B1
Di Pompeo, C1
Dewavrin, F1
Favory, R1
Roussel-Delvallez, M1
Durocher, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment (The CANTREAT Study): A Prospective, Randomized, Double Blind, Placebo Controlled Pilot Study[NCT00934934]Phase 261 participants (Actual)Interventional2010-04-30Terminated (stopped due to slow enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

(SOFA) Post Randomization

Sequential organ failure assessment. 0-24 The higher the number the more severe organ failure (NCT00934934)
Timeframe: post randomization

Interventionscore on a scale (Mean)
Placebo5.9
Antifungal5.9

Antibiotic Free Days 28-day Post Randomization

Number of days free of antibiotic use within the first 28 days (NCT00934934)
Timeframe: 28 days

Interventiondays (Median)
Placebo16
Antifungal10

B-glucan Levels

(NCT00934934)
Timeframe: 28 days

Interventionpg/ml (Mean)
VAP withCandida116
VAP Without Candida129.1

C-reactive Protein

(NCT00934934)
Timeframe: 28 days

Interventionmg/l (Mean)
VAP withCandida133
VAP Without Candida145.7

Duration of Stay in ICU

Measure of the duration of participant stay in the ICU (NCT00934934)
Timeframe: 28 days

Interventiondays (Median)
Placebo11.5
Antifungal13

Hospital Length of Stay

Measure of the duration of the participant's hospital stay (NCT00934934)
Timeframe: 90 days

Interventiondays (Median)
Placebo29
Antifungal28

ICU Free Days

Number of days free of ICU (NCT00934934)
Timeframe: 28 days

Interventiondays (Median)
Placebo14
Antifungal4

Interleukin-6

(NCT00934934)
Timeframe: 28 days

Interventionpg/ml (Mean)
VAP withCandida97.5
VAP Without Candida3

Overall Recruitment Rate

Overall recruitment rate per site (NCT00934934)
Timeframe: 32 months

Interventionparticipants per site /month (Number)
Overall0.6

Sequential Procalcitonin

(NCT00934934)
Timeframe: 28 days

Interventionng/ml (Mean)
VAP withCandida3.0
VAP Without Candida22.5

Ventilator Free Days

Number of days in ICU free of ventilation (NCT00934934)
Timeframe: 28 days

Interventiondays (Median)
Placebo8
Antifungal9

Reviews

1 review available for fluconazole and Ventilator-Associated Pneumonia

ArticleYear
Prevention of nosocomial infections in neonatal intensive care units.
    American journal of perinatology, 2013, Volume: 30, Issue:2

    Topics: Anti-Infective Agents; Central Venous Catheters; Contraindications; Cross Infection; Fluconazole; Hi

2013

Other Studies

1 other study available for fluconazole and Ventilator-Associated Pneumonia

ArticleYear
Impact of antifungal treatment on Candida-Pseudomonas interaction: a preliminary retrospective case-control study.
    Intensive care medicine, 2007, Volume: 33, Issue:1

    Topics: Antifungal Agents; Bronchi; Candida; Case-Control Studies; Female; Fluconazole; Humans; Male; Middle

2007